Literature DB >> 24018050

RIO kinase 3 acts as a SUFU-dependent positive regulator of Hedgehog signaling.

Melanie Tariki1, Sarah Alexandra Wieczorek, Philipp Schneider, Sebastian Bänfer, Sophie Veitinger, Ralf Jacob, Volker Fendrich, Matthias Lauth.   

Abstract

Suppressor of fused (SUFU) is an essential negative regulator of the mammalian Hedgehog (HH) signaling pathway and its loss is associated with cancer development. On a cellular level, endogenous SUFU can mainly be detected in the cytoplasm and the nucleus. However, immunostaining of pancreatic cancer specimen revealed the existence of cell types showing selective enrichment of endogenous SUFU in the nucleus. Following up on this observation, we found that a SUFU construct which was experimentally tethered exclusively to the nucleus was unable to antagonize endogenous HH signaling, in contrast to control SUFU. These data suggest that alterations in the normal subcellular distribution of SUFU might interfere with its established negative role on the HH pathway. Performing a multi-well kinase screen in human cells identified RIO kinase 3 (RIOK3) as a novel modulator of SUFU subcellular distribution. Functionally, RIOK3 acts as a SUFU-dependent positive regulator of HH signaling. Taken together, we propose that factors modulating the nucleo-cytoplasmic distribution of SUFU impact on the normal function of this tumor suppressing protein.
© 2013.

Entities:  

Keywords:  GLI; GLI1; HH; Hedgehog; RIOK3; SHH; SUFU; Signal transduction; glioma-associated oncogene 1; hedgehog; right open reading frame kinase 3; sonic hedgehog; suppressor of fused

Mesh:

Substances:

Year:  2013        PMID: 24018050     DOI: 10.1016/j.cellsig.2013.08.037

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

1.  DYRK1B regulates Hedgehog-induced microtubule acetylation.

Authors:  Rajeev Singh; Philipp Simon Holz; Katrin Roth; Anna Hupfer; Wolfgang Meissner; Rolf Müller; Malte Buchholz; Thomas M Gress; Hans-Peter Elsässer; Ralf Jacob; Matthias Lauth
Journal:  Cell Mol Life Sci       Date:  2018-10-13       Impact factor: 9.261

2.  RIOK3 is an adaptor protein required for IRF3-mediated antiviral type I interferon production.

Authors:  Jun Feng; Paul D De Jesus; Victoria Su; Stephanie Han; Danyang Gong; Nicholas C Wu; Yuan Tian; Xudong Li; Ting-Ting Wu; Sumit K Chanda; Ren Sun
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

3.  A systematic pan-cancer analysis identifies RIOK3 as an immunological and prognostic biomarker.

Authors:  Jian Li; Ruili Sun; Lixiang He; Guoyi Sui; Wenyu Di; Jian Yu; Wei Su; Zenggang Pan; Yu Zhang; Jinghang Zhang; Feng Ren
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

4.  Investigating the role of RIO protein kinases in Caenorhabditis elegans.

Authors:  Tasha K Mendes; Stevan Novakovic; Greta Raymant; Sonja E Bertram; Reza Esmaillie; Saravanapriah Nadarajan; Bert Breugelmans; Andreas Hofmann; Robin B Gasser; Monica P Colaiácovo; Peter R Boag
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

5.  DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway.

Authors:  Rajeev Singh; Pavan Kumar Dhanyamraju; Matthias Lauth
Journal:  Oncotarget       Date:  2017-01-03

6.  LIFR-AS1 modulates Sufu to inhibit cell proliferation and migration by miR-197-3p in breast cancer.

Authors:  Fangfang Xu; Hui Li; Chengjiu Hu
Journal:  Biosci Rep       Date:  2019-07-08       Impact factor: 3.840

7.  High Expression of RIOK2 and NOB1 Predict Human Non-small Cell Lung Cancer Outcomes.

Authors:  Kun Liu; Hong-Lin Chen; Shuo Wang; Ming-Ming Gu; Xin-Ming Chen; Shuang-Long Zhang; Kang-Jun Yu; Qing-Sheng You
Journal:  Sci Rep       Date:  2016-06-27       Impact factor: 4.379

8.  Riok3 inhibits the antiviral immune response by facilitating TRIM40-mediated RIG-I and MDA5 degradation.

Authors:  Yong Shen; Kejun Tang; Dongdong Chen; Mengying Hong; Fangfang Sun; SaiSai Wang; Yuehai Ke; Tingting Wu; Ren Sun; Jing Qian; Yushen Du
Journal:  Cell Rep       Date:  2021-06-22       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.